SavedAdd your journal

Journals / Online Türk Sağlık Bilimleri Dergisi / 2026 / Cilt: 7 Sayı: 3

The Attitudes of the Patients with the Multisystem Inflammatory Syndrome in Children Secondary to SARS-CoV-2 Regarding COVID-19 Vaccines

Çocuklarda COVID-19’a İkincil Gelişen Multisistemik İnflamatuar Sendrom Tanılı Hastaların COVID-19 Aşısına Karşı Tutumları

Eviç Zeynep Akgün(KOCAELI UNIVERSITY)0000-0003-1987-8465
Dicle Aydın(KOCAELI UNIVERSITY)0000-0003-4377-5327
Hafize Emine Sönmez(KOCAELI UNIVERSITY)0000-0002-9186-3068
Kadir Babaoğlu(KOCAELI UNIVERSITY)0000-0001-9026-0532
Pages
468–472
Publication Date
2022-09-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we aimed to present the attitudes of MIS-C patients over the age of 12 years towards the COVID-19 vaccine, and the side effects of the vaccine in vaccinated patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Multisystem inflammatory syndrome (MIS-C) in children is an abnormal immune response that occurs after exposure to SARS-CoV-2.
📊
Key Findings & Data:To our knowledge, there is no study demonstrating the efficacy and safety of the BNT162b2 mRNA vaccine in children who were diagnosed with MIS-C previously.
💡
Conclusion & Impact:In this study, we aimed to present the attitudes of MIS-C patients over the age of 12 years towards the COVID-19 vaccine, and the side effects of the vaccine in vaccinated patients.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Aşı güvenliği · BNT162b2 mRNA aşısı · çocuklarda multisistemik inflamatuar sendrom

Abstract

Objective: Multisystem inflammatory syndrome (MIS-C) in children is an abnormal immune response that occurs after exposure to SARS-CoV-2. To our knowledge, there is no study demonstrating the efficacy and safety of the BNT162b2 mRNA vaccine in children who were diagnosed with MIS-C previously. In this study, we aimed to present the attitudes of MIS-C patients over the age of 12 years towards the COVID-19 vaccine, and the side effects of the vaccine in vaccinated patients.

Özet

Amaç: Çocuklarda multisistemik inflamatuar sendrom (MIS-C); SARS-CoV-2 ile enfekte olduktan sonra ortaya çıkan anormal bir bağışıklık yanıtıdır. Bu hastalarda BNT162b2 mRNA aşısının etkinliğini ve güvenliğini ortaya koyan bir çalışma yoktur. Bu çalışmada MIS-C tanısı almış 12 yaşın üzerindeki hastalarımızın COVID-19 aşısına karşı tutumları ve eğer aşılandılarsa gelişen yan etkileri sunmayı amaçladık.

🔖

Cite This Article

Akgün, E. Z., Aydın, D., Sönmez, H. E., Babaoğlu, K. (2022). The Attitudes of the Patients with the Multisystem Inflammatory Syndrome in Children Secondary to SARS-CoV-2 Regarding COVID-19 Vaccines. Online Türk Sağlık Bilimleri Dergisi, Cilt: 7 Sayı: 3, 468–472. https://doi.org/10.26453/otjhs.1095563

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334-346. doi:10.1056/NEJMoa2021680
  2. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347-358. doi:10.1056/NEJMoa2021756
  3. Centers for Disease Control andPrevention. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Corona virus Disease 2019 (COVID-19) 2020. https://emergency.cdc.gov/han/2020/han00432.asp. Accessed March 20, 2022.
  4. Hause AM, Baggs J, Marquez P, et al. COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December19, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(5152):1755–1760. doi:10.15585/mmwr.mm705152a1
  5. Yousaf AR, Cortese MM, Taylor AW, et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: A surveillance investigation. Lancet Child Adolesc Health. 2022;6(5): 3030-312. doi:10.1016/S2352-4642(22)00028-1
  6. Levy M, Recher M, Hubert H, et al. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA. 2022;327(3):281-283. doi:10.1001/jama.2021.23262
  7. Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years—United States, July–December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):52–58. doi:10.155585/mmwr.mm7102e1
  8. Buchhorn R, Meyer C, Schulze-Forster K, Junker J, Heidecke H. Autoantibody release in children after corona virus mRNA vaccination: A risk factor of multisystem inflammatory syndrome? Vaccines (Basel). 2021;9(11):1353. doi:10.3390/vaccines9111353
  9. Chin SE, Bhavsar SM, Corson A, Ghersin ZJ, Kim HS. Cardiac complications associated with COVID-19, MIS-C, and mRNA COVID-19 vaccination. Pediatr Cardiol. 2022;43(3):483-488. doi:10.1007/s00246-022-02851-x
  10. Centers for Disease Control and Prevention. The vaccine adverse event reporting system (VAERS) results 2021. https://wonder.cdc.gov/vaers.html. Accessed December 2, 2021.
  11. Rostad CA, Chahroudi A, Mantus G, et al. Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C). Pediatrics. 2020;146:e2020018242. doi:10.1542/peds.2020-018242
  12. Yonker LM, Neilan AM, Bartsch Y, et al. Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): clinical presentation, infectivity, and immune responses. J Pediatr. 2020;227:45–52.e5. doi:10.1016/j.jpeds.2020.08.037
  13. Trougakos IP, Terpos E, Zirou C, et al. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgG s and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021;19:208. doi:10.1186/s129-021-02090-6
  14. T.C. Sağlık Bakanlığı COVID-19 aşısı bilgilendirme platformu 2022. https://covid19asi.saglik.gov.tr/. Accessed March 24, 2022.
  15. Türkiye Nüfusu Yaş Gruplarına Göre Dağılımı 2021. https://www.nufusu.com/turkiye-nufusu-yas-gruplari. Accessed March 24, 2022.
  16. Akgün Ö, Çakmak F, Guliyeva V, Demirkan FG, Tanatar A, Hançerli Torun S, Çin D, Meşe S, Ağaçfidan A, Aktay Ayaz N. Rheumatology (Oxford). 2022. doi:10.1093/rheumatology/keac140